BioCryst Pharmaceuticals, Inc. (BCRX) reported on Friday that its preliminary unaudited total revenue for the fourth quarter of 2024 reached $130.8 million, which signifies a 40% increase compared to the previous year. For the entire year 2024, preliminary unaudited total revenue amounted to $450 million, marking a 36% rise over the prior year.
Additionally, the preliminary net revenue for ORLADEYO in 2024 was $437 million, a 34% increase from the previous year. Specifically, for the fourth quarter, ORLADEYO’s net revenue surged to $123.5 million, a 36% year-over-year growth.
Looking forward, BioCryst projects that global net revenue for ORLADEYO in 2025 will range from $515 million to $535 million. The company also forecasts that total revenue, which includes RAPIVAB, will fall between $540 million and $560 million for the same period.
Furthermore, the company anticipates achieving near-quarterly positive earnings per share (EPS) and positive cash flow by the latter half of 2025. BioCryst aims to be profitable on an EPS basis with a positive cash flow for the entire year 2026.
In pre-market trading, BioCryst's shares are valued at $8.10, reflecting a 0.62% increase on the Nasdaq.
